AB Science (AB)

Executive Summary

AB Science is a French biotechnology company specializing in small molecule protein kinase inhibitors. Its lead compound, masitinib, is a highly selective tyrosine kinase inhibitor being developed for oncology, neurodegenerative diseases (e.g., ALS, Alzheimer's), and inflammatory conditions. The company also has an early-stage candidate, AB8939, a novel microtubule destabilizer. Masitinib has shown promising efficacy in Phase 2/3 trials, particularly in ALS where it met its primary endpoint in a Phase 3 study, and is currently under regulatory review in Europe for certain indications. AB8939 is in Phase 1 development for hematologic malignancies. With a rich pipeline and multiple value-driving catalysts, AB Science is positioned to address high unmet medical needs.

Upcoming Catalysts (preview)

• Q3 2026Masitinib Phase 3 ALS Data and Regulatory Filing70% success
• Q4 2026AB8939 Phase 1 Safety and Efficacy Data50% success
• TBDPotential Partnership or Licensing Deal for Masitinib in Oncology40% success